Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

PHASE3UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

June 15, 2024

Study Completion Date

January 15, 2025

Conditions
Hepatitis Delta Virus
Interventions
DRUG

Peginterferon Lambda-1a

Immunomodulator

Trial Locations (48)

1020

CHU Brugmann, Brussels

1407

Acibadem City Clinic Tokuda Hospital, Sofia

2025

Institutul de Cardiologie Chisinau, Chisinau

2650

University Hospital Antwerp, Edegem

6001

"Medical Center Nov Rehabilitatsionen Centre EOOD", Stara Zagora

10016

NYU Langone Health / NYU Grossman School of Medicine, New York

10029

Icahn School of Medicine - Mount Sinai Medical Center, New York

20122

Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan

21280

Dicle University, Medical Faculty, Diyarbakır

30625

Medizinische Hochschule Hannover, Hanover

31059

CHU Toulouse, Toulouse

34000

Hopital Saint Eloi, Montpellier

34098

Istanbul Universitry-Cerrahapasa, Cerrahpasa School of Medicine, Istanbul

35100

Ege University Medical Faculty, Bornova

38043

CHU Grenoble-Alpes, Grenoble

41013

Hospital Universitario Virgen del Rocío, Seville

55131

Universitätsmedizin Mainz, I. Med. Klinik, Mainz

56124

Azienda Ospedaliero Universitaria Pisana, Pisa

60590

ZIM 1, Gastroenterologie, University Hospital Frankfurt, Frankfurt

60612

Rush University Medical Center, Chicago

63100

CHU Clermont-Ferrand, Clermont-Ferrand

76031

CHU de Rouen, Rouen

90020

Asian Pacific Liver Center at Coalition of Inclusive Medicine, Los Angeles

90033

Keck Medical Center of USC, Los Angeles

91120

Hadassah University Hospital - Ein Kerem, Jerusalem

92110

Hôpital Beaujon, Clichy

93000

APHP, Hôpital Avicenne, Bobigny

94000

Henri-Mondor Hospital, Créteil

94063

Stanford Medicine Outpatient Center, Redwood City

94109

Sutter Pacific Medical Foundation - California Pacific Medical Center, San Francisco

1834113

Emek Medical Center, Afula

3109601

Rambam Health Care Center, Haifa

5262000

The Liver Diseases Center, Sheba Medical Center, Ramat Gan

B-1070

CUB Hôpital Erasme, Brussels

0144

LTD,Tbilisi State Medical Univeristy and lngorokva High Medical Technology University Clinic, Tbilisi

0160

Infectious diseases, AIDS and Clinical Immunology Research Center, Tbilisi

LTD Academician Nikoloz Kipshidze Central University Clinic, Tbilisi

Unknown

Soroka University Medical Center, Beersheba

Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, Foggia

Fundeni Clinical Institute, Bucharest

"National Institute for Infectious Diseases Matei Bals", Bucharest

Spitalul de Infectioase Galati Romania, Galati

Hospital Universitario Fundación Alcorcón, Madrid

Ankara City Hospital, Ankara

Hacettepe University Medical Faculty, Ankara

Koc University Hospital, Istanbul

030303

Dr. Victor Babes Foundation, Bucharest

08035

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Eiger BioPharmaceuticals

INDUSTRY

NCT05070364 - Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV | Biotech Hunter | Biotech Hunter